1022158-35-5

Basic information

• Product Name: 4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole
• Synonyms: 4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole;4-bromo-1-(oxan-2-yl)-1H-indazole
• CAS NO: 1022158-35-5
• Molecular Formula: C₁₂H₁₃BrN₂O
• Molecular Weight: 281.14842
• Mol File: 1022158-35-5.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(1022158-35-5)
• EPA Substance Registry System: 4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole(1022158-35-5)

Safety Data

• Hazardous Substances Data: 1022158-35-5(Hazardous Substances Data)

Usage

General Description

4-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole, also known as THPI, is a chemical compound that belongs to the indazole class of compounds. It is characterized by the presence of a bromine atom and a tetrahydro-2H-pyran-2-yl group attached to the indazole core. 4-BroMo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole has been studied for its potential pharmacological properties, particularly its activity on cannabinoid receptors. It has been identified as a potent and selective ligand for the cannabinoid type 2 (CB2) receptor, making it a potential candidate for the development of therapeutic agents for a range of conditions, including pain, inflammation, and neurodegenerative diseases. Research on THPI and its derivatives continues to explore its biological activity and potential applications in medicine.

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 186407-74-9 4-bromoindazole 
• 55289-36-6 3-bromo-2-methylaniline 
• 1073-06-9 3-fluorobromobenzene 
• 360575-28-6 2-bromo-6-fluorobenzaldehyde 

Downstream Products

• 1022158-36-6 1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-4-carbaldehyde 

Relevant articles and documents

Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition

Recently, PI3K and mTOR have been regarded as promising targets for cancer treatment. Herein, we designed and synthesized four series of novel thieno[3,2-d]pyrimidine derivatives that containing aroyl hydrazone or aryl hydrazide moieties. These derivatives act as PI3K/mTOR dual inhibitors, suggesting that they can be used as cancer therapeutic agents. All compounds were tested for anti-proliferative activity against four cancer cell lines. The structure-activity relationship (SAR) studies were conducted by varying the moieties at the C-6 and C-2 positions of the thieno[3,2-d]pyrimidine core. It indicated that aryl hydrazide at C-6 position and 2-aminopyrimidine at C-2 position are optimal fragments. Compound 18b showed the most potent in vitro activity (PI3Kα IC50 = 0.46 nM, mTOR IC50 = 12 nM), as well as good inhibition against PC-3 (human prostate cancer), HCT-116 (human colorectal cancer), A549 (human lung adenocarcinoma) and MDA-MB-231 (human breast cancer) cell lines. Furthermore, Annexin-V and propidium iodide (PI) double staining confirmed that 18b induces apoptosis in cytotoxic HCT-116 cells. Moreover, the influence of 18b on cell cycle distribution was assessed on the HCT-116 cell line, and a cell cycle arrest was observed at the G1/S phases.

POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS

The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X-Y-Z (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.

Application of C-H Functionalization in the Development of a Concise and Convergent Route to the Phosphatidylinositol-3-kinase Delta Inhibitor Nemiralisib

This paper describes the development of an improved and scalable method for the manufacture of nemiralisib, a phosphatidylinositol-3-kinase delta inhibitor. Incorporation of three consecutive catalytic reactions, including a palladium-catalyzed C-H functionalization and an iridium-catalyzed borylation, significantly simplified and shortened the synthetic sequence. The revised route was successfully implemented in a pilot plant on a multikilogram scale to deliver >100 kg of product.